174 related articles for article (PubMed ID: 35237846)
1. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH
Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846
[TBL] [Abstract][Full Text] [Related]
2. Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Ingram JR; Blomberg OS; Rashidian M; Ali L; Garforth S; Fedorov E; Fedorov AA; Bonanno JB; Le Gall C; Crowley S; Espinosa C; Biary T; Keliher EJ; Weissleder R; Almo SC; Dougan SK; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):3912-3917. PubMed ID: 29581255
[TBL] [Abstract][Full Text] [Related]
3. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Jenkins KA; Park M; Pederzoli-Ribeil M; Eskiocak U; Johnson P; Guzman W; McLaughlin M; Moore-Lai D; O'Toole C; Liu Z; Nicholson B; Flesch V; Qiu H; Clackson T; O'Hagan RC; Rodeck U; Karow M; O'Neil J; Williams JC
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164757
[TBL] [Abstract][Full Text] [Related]
4. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
5. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
[TBL] [Abstract][Full Text] [Related]
6. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
[TBL] [Abstract][Full Text] [Related]
7. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
8. An anti-CTLA-4 heavy chain-only antibody with enhanced T
Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
[TBL] [Abstract][Full Text] [Related]
9. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
10. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas F; Furness AJS; Litchfield K; Joshi K; Rosenthal R; Ghorani E; Solomon I; Lesko MH; Ruef N; Roddie C; Henry JY; Spain L; Ben Aissa A; Georgiou A; Wong YNS; Smith M; Strauss D; Hayes A; Nicol D; O'Brien T; Mårtensson L; Ljungars A; Teige I; Frendéus B; ; ; ; Pule M; Marafioti T; Gore M; Larkin J; Turajlic S; Swanton C; Peggs KS; Quezada SA
Cancer Cell; 2018 Apr; 33(4):649-663.e4. PubMed ID: 29576375
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
12. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
13. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
[TBL] [Abstract][Full Text] [Related]
14. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
15. Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.
Davis-Marcisak EF; Fitzgerald AA; Kessler MD; Danilova L; Jaffee EM; Zaidi N; Weiner LM; Fertig EJ
Genome Med; 2021 Aug; 13(1):129. PubMed ID: 34376232
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
[TBL] [Abstract][Full Text] [Related]
17. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Graziani G; Lisi L; Tentori L; Navarra P
Exp Suppl; 2022; 113():295-350. PubMed ID: 35165868
[TBL] [Abstract][Full Text] [Related]
19. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
20. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
